A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
Status:
Recruiting
Trial end date:
2021-11-29
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label and active controlled phase II study. It plans
to enroll 60 subjects with extensive stage small cell lung cancer (ES-SCLC). All subjects
will be assigned randomly to the experimental arm or control arm. The primary endpoints would
be overall survival and progression-free survival.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University